Close

Leerink Swann Maintains an 'Outperform' on InterMune (ITMN); Lowering PT on Delays in Expected Esbriet Launch

April 9, 2012 7:15 AM EDT
Get Alerts ITMN Hot Sheet
Price: $73.89 --0%

Rating Summary:
    8 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on InterMune Inc. (NASDAQ: ITMN) price target lowered from $37 to $27.

Analyst, Jonathan Eckard, said, "We are lowering our 12-month valuation on ITMN shares to $27, reflecting the delays in expected Esbriet launch in several EU countries and in the US, as well as more modest assumptions on German ramp-up. We reach our $27 valuation using a DCF analysis that assumes sales of Esbriet in Europe and probability-weighted US sales (at 65%) with IP protection only from the respective 10- and 7-years of orphan drug exclusivity. This DCF uses an 11% discount rate that we believe is appropriate given the inclusion of probability-weighted sales."

For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.

Shares of InterMune Inc. closed at $15.28 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change